BACKGROUND: Menopause is associated with urine phosphorus retention, which is mitigated by estrogen therapy. Fibroblast growth factor 23 (FGF-23) is a hormone originating from bone that regulates urine phosphorus excretion. Whether sex or estrogen therapy is associated with different FGF-23 levels is unknown. STUDY DESIGN & SETTING: Cross-sectional study of ambulatory individuals with prevalent cardiovascular disease. PREDICTORS: Sex and, in women, use or nonuse of estrogen. OUTCOMES: Serum phosphorus, tubular maximum reabsorption of phosphorus indexed to glomerular filtration rate (TMP/GFR), and plasma FGF-23 concentrations. RESULTS: For 987 participants, mean age was 67 ± 11 years, 182 (18%) were women, and 46 (25%) were using estrogen. Mean estimated GFR was 71 ± 23 (SD) mL/min/1.73 m(2). Compared with women who were not using estrogen, both women on estrogen therapy and men had significantly lower serum phosphorus concentrations, lower TMP/GFR values (indicating higher urine phosphorus excretion), and lower FGF-23 concentrations with adjustment for age, demographics, and kidney function (P < 0.001 for each). Mean FGF-23 levels were 68.7 (95% CI, 59.7-79.0) relative units (RU)/mL in non-estrogen-using women, 43.8 (95% CI, 41.2-46.5) RU/mL in men, and 45.1 (95% CI, 35.2-57.4) RU/mL in women using estrogen in adjusted analysis (P < 0.001). LIMITATIONS: Most participants were men. Estrogen therapy was not randomly assigned. CONCLUSIONS: Older women who are not using estrogen have higher FGF-23 levels than either men or women using estrogen. In the context of prior literature, these data suggest that postmenopausal phosphorus retention may stimulate higher FGF-23 concentrations after menopause. Published by Elsevier Inc.
BACKGROUND: Menopause is associated with urine phosphorus retention, which is mitigated by estrogen therapy. Fibroblast growth factor 23 (FGF-23) is a hormone originating from bone that regulates urine phosphorus excretion. Whether sex or estrogen therapy is associated with different FGF-23 levels is unknown. STUDY DESIGN & SETTING: Cross-sectional study of ambulatory individuals with prevalent cardiovascular disease. PREDICTORS: Sex and, in women, use or nonuse of estrogen. OUTCOMES: Serum phosphorus, tubular maximum reabsorption of phosphorus indexed to glomerular filtration rate (TMP/GFR), and plasma FGF-23 concentrations. RESULTS: For 987 participants, mean age was 67 ± 11 years, 182 (18%) were women, and 46 (25%) were using estrogen. Mean estimated GFR was 71 ± 23 (SD) mL/min/1.73 m(2). Compared with women who were not using estrogen, both women on estrogen therapy and men had significantly lower serum phosphorus concentrations, lower TMP/GFR values (indicating higher urine phosphorus excretion), and lower FGF-23 concentrations with adjustment for age, demographics, and kidney function (P < 0.001 for each). Mean FGF-23 levels were 68.7 (95% CI, 59.7-79.0) relative units (RU)/mL in non-estrogen-using women, 43.8 (95% CI, 41.2-46.5) RU/mL in men, and 45.1 (95% CI, 35.2-57.4) RU/mL in women using estrogen in adjusted analysis (P < 0.001). LIMITATIONS: Most participants were men. Estrogen therapy was not randomly assigned. CONCLUSIONS: Older women who are not using estrogen have higher FGF-23 levels than either men or women using estrogen. In the context of prior literature, these data suggest that postmenopausal phosphorus retention may stimulate higher FGF-23 concentrations after menopause. Published by Elsevier Inc.
Authors: Joachim H Ix; Glenn M Chertow; Michael G Shlipak; Vincent M Brandenburg; Markus Ketteler; Mary A Whooley Journal: Nephrol Dial Transplant Date: 2006-04-27 Impact factor: 5.992
Authors: Thomas Thom; Nancy Haase; Wayne Rosamond; Virginia J Howard; John Rumsfeld; Teri Manolio; Zhi-Jie Zheng; Katherine Flegal; Christopher O'Donnell; Steven Kittner; Donald Lloyd-Jones; David C Goff; Yuling Hong; Robert Adams; Gary Friday; Karen Furie; Philip Gorelick; Brett Kissela; John Marler; James Meigs; Veronique Roger; Stephen Sidney; Paul Sorlie; Julia Steinberger; Sylvia Wasserthiel-Smoller; Matthew Wilson; Philip Wolf Journal: Circulation Date: 2006-01-11 Impact factor: 29.690
Authors: Rupal Mehta; Alexander Hodakowski; Xuan Cai; Kris E Lee; Bryan R Kestenbaum; Ian H de Boer; Amani Fawzi; Tien Yin Wong; Joachim Ix; Barbara Klein; Ronald Klein; Tamara Isakova Journal: Ophthalmic Epidemiol Date: 2017-04-12 Impact factor: 1.648
Authors: Rakesh Malhotra; Ronit Katz; Andrew Hoofnagle; Andrew Bostom; Dena E Rifkin; Ruth Mcbride; Jeffrey Probstfield; Geoffrey Block; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2017-12-05 Impact factor: 8.237
Authors: Bhupesh Panwar; Suzanne E Judd; Virginia G Wadley; Nancy S Jenny; Virginia J Howard; Monika M Safford; Orlando M Gutiérrez Journal: JAMA Cardiol Date: 2018-04-01 Impact factor: 14.676
Authors: Nisha Bansal; Ronit Katz; Ian H de Boer; Bryan Kestenbaum; David S Siscovick; Andrew N Hoofnagle; Russell Tracy; Gail A Laughlin; Michael H Criqui; Mathew J Budoff; Dong Li; Joachim H Ix Journal: J Clin Endocrinol Metab Date: 2013-10-03 Impact factor: 5.958
Authors: Charles Ginsberg; Alfons J H M Houben; Rakesh Malhotra; Tos T J M Berendschot; Pieter C Dagnelie; Jeroen P Kooman; Caroll A Webers; Coen D A Stehouwer; Joachim H Ix Journal: Clin J Am Soc Nephrol Date: 2019-09-20 Impact factor: 8.237
Authors: Clinton B Wright; Nirav H Shah; Armando J Mendez; Janet T DeRosa; Mitsuhiro Yoshita; Mitchell S V Elkind; Ralph L Sacco; Charles DeCarli; Tatjana Rundek; Shonni Silverberg; Chuanhui Dong; Myles Wolf Journal: Stroke Date: 2016-03-08 Impact factor: 7.914